{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:24Z","timestamp":1787800824996,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10620-026-09887-6","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T01:48:19Z","timestamp":1776044899000},"page":"4062-4076","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-7061","authenticated-orcid":false,"given":"Syed Anjum Ali","family":"Gardezi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Javaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ulhaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutaiba","family":"Albustanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaroon Bin","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"9887_CR1","doi-asserted-by":"publisher","unstructured":"Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649\u2013670. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx008","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"9887_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. The Lancet. 2017;389:1756\u20131770. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"The Lancet."},{"key":"9887_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769\u20132778. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"The Lancet."},{"key":"9887_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cgh.2019.07.022","volume":"18","author":"GR Lichtenstein","year":"2020","unstructured":"Lichtenstein GR, Shahabi A, Seabury SA et al. Lifetime Economic Burden of Crohn\u2019s Disease and Ulcerative Colitis by Age at Diagnosis. Clinical Gastroenterology and Hepatology. 2020;18:889-897.e10. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.022.","journal-title":"Clinical Gastroenterology and Hepatology."},{"key":"9887_CR5","doi-asserted-by":"publisher","unstructured":"Feagan BG, Chande N, MacDonald JK. Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflamm Bowel Dis. Published online June 2013:1. https:\/\/doi.org\/10.1097\/MIB.0b013e3182920108","DOI":"10.1097\/MIB.0b013e3182920108"},{"key":"9887_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/apt.13076","volume":"41","author":"WJ Sandborn","year":"2015","unstructured":"Sandborn WJ, Danese S, D\u2019Haens G et al. Induction of clinical and colonoscopic remission of mild\u2013to\u2013moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41:409\u2013418. https:\/\/doi.org\/10.1111\/apt.13076.","journal-title":"Aliment Pharmacol Ther."},{"key":"9887_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/jcm9010094","volume":"9","author":"M Kayal","year":"2019","unstructured":"Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med. 2019;9:94. https:\/\/doi.org\/10.3390\/jcm9010094.","journal-title":"J Clin Med."},{"key":"9887_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","volume":"29","author":"AM Subei","year":"2015","unstructured":"Subei AM, Cohen JA. Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015;29:565\u2013575. https:\/\/doi.org\/10.1007\/s40263-015-0261-z.","journal-title":"CNS Drugs."},{"key":"9887_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/imt-2022-0255","volume":"15","author":"P Wils","year":"2023","unstructured":"Wils P, Peyrin-Biroulet L. Etrasimod for the Treatment of Ulcerative Colitis. Immunotherapy. 2023;15:311\u2013321. https:\/\/doi.org\/10.2217\/imt-2022-0255.","journal-title":"Immunotherapy."},{"key":"9887_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","volume":"23","author":"OH Nielsen","year":"2017","unstructured":"Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. Trends Mol Med. 2017;23:362\u2013374. https:\/\/doi.org\/10.1016\/j.molmed.2017.02.002.","journal-title":"Trends Mol Med."},{"key":"9887_CR11","doi-asserted-by":"publisher","unstructured":"Danese S, Furfaro F, Vetrano S. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. J Crohns Colitis. 2018;12(suppl_2):S678-S686. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx107","DOI":"10.1093\/ecco-jcc\/jjx107"},{"key":"9887_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S2468-1253(24)00386-8","volume":"10","author":"BE Sands","year":"2025","unstructured":"Sands BE, Panaccione R, D\u2019Haens G et al. Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025;10:210\u2013221. https:\/\/doi.org\/10.1016\/S2468-1253(24)00386-8.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9887_CR13","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"9887_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583.","journal-title":"PLoS Med."},{"key":"9887_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 2023;401:1159\u20131171. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"The Lancet."},{"key":"9887_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000541383","volume":"106","author":"K Takeuchi","year":"2024","unstructured":"Takeuchi K, Hisamatsu T, Nakase H et al. Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials. Digestion. 2024;106:167\u2013175. https:\/\/doi.org\/10.1159\/000541383.","journal-title":"Digestion."},{"key":"9887_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158:550\u2013561. https:\/\/doi.org\/10.1053\/j.gastro.2019.10.035.","journal-title":"Gastroenterology."},{"key":"9887_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000509393","volume":"5","author":"HH Radeke","year":"2020","unstructured":"Radeke HH, Stein J, Van Assche G et al. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflamm Intest Dis. 2020;5:180\u2013190. https:\/\/doi.org\/10.1159\/000509393.","journal-title":"Inflamm Intest Dis."},{"key":"9887_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. Published online August 28, 2019:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"9887_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4097\/kja.21080","volume":"74","author":"TP Tantry","year":"2021","unstructured":"Tantry TP, Karanth H, Shetty PK, Kadam D. Self-learning software tools for data analysis in meta-analysis. Korean J Anesthesiol. 2021;74:459\u2013461. https:\/\/doi.org\/10.4097\/kja.21080.","journal-title":"Korean J Anesthesiol."},{"key":"9887_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 2021;385:1280\u20131291. https:\/\/doi.org\/10.1056\/NEJMoa2033617.","journal-title":"New England Journal of Medicine."},{"key":"9887_CR22","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Feagan BG, Wolf DC et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine. 2016;374:1754\u20131762. https:\/\/doi.org\/10.1056\/NEJMoa1513248.","journal-title":"New England Journal of Medicine."},{"key":"9887_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S2468-1253(25)00198-0","volume":"10","author":"K Wu","year":"2025","unstructured":"Wu K, Zheng C, Cao Q et al. Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2025;10:1089\u20131103. https:\/\/doi.org\/10.1016\/S2468-1253(25)00198-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9887_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00011-023-01829-6","volume":"73","author":"HA Suilik","year":"2024","unstructured":"Suilik HA, Jaber F, Abuelazm M et al. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Inflammation Research. 2024;73:183\u2013198. https:\/\/doi.org\/10.1007\/s00011-023-01829-6.","journal-title":"Inflammation Research."},{"key":"9887_CR25","doi-asserted-by":"publisher","unstructured":"Zou F, Wang S, Xu M, Wu Z, Deng F. The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases. Front Physiol. 2023;14. https:\/\/doi.org\/10.3389\/fphys.2023.1235656","DOI":"10.3389\/fphys.2023.1235656"},{"key":"9887_CR26","first-page":"265","volume":"18","author":"T Choden","year":"2022","unstructured":"Choden T, Cohen NA, Rubin DT. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2022;18:265\u2013271.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"9887_CR27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","volume":"84","author":"K Kitsou","year":"2024","unstructured":"Kitsou K, Kokkotis G, Rivera-Nieves J, Bamias G. Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management. Drugs. 2024;84:1179\u20131197. https:\/\/doi.org\/10.1007\/s40265-024-02094-5.","journal-title":"Drugs."},{"key":"9887_CR28","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1096\/fj.10-179028","volume":"25","author":"T Schulze","year":"2011","unstructured":"Schulze T, Golfier S, Tabeling C et al. Sphingosine-1-phospate receptor 4 (S1P 4) deficiency profoundly affects dendritic cell function and T H 17-cell differentiation in a murine model. The FASEB Journal. 2011;25:4024\u20134036. https:\/\/doi.org\/10.1096\/fj.10-179028.","journal-title":"The FASEB Journal."},{"key":"9887_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3748\/wjg.v29.i1.110","volume":"29","author":"E Tourkochristou","year":"2023","unstructured":"Tourkochristou E, Mouzaki A, Triantos C. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases. World J Gastroenterol. 2023;29:110\u2013125. https:\/\/doi.org\/10.3748\/wjg.v29.i1.110.","journal-title":"World J Gastroenterol."},{"key":"9887_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107464","volume":"207","author":"OA Sukocheva","year":"2020","unstructured":"Sukocheva OA, Furuya H, Ng ML et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther. 2020;207:107464. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107464.","journal-title":"Pharmacol Ther."},{"key":"9887_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006343","volume":"11","author":"G Gao","year":"2023","unstructured":"Gao G, Liao W, Shu P et al. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor. J Immunother Cancer. 2023;11:e006343. https:\/\/doi.org\/10.1136\/jitc-2022-006343.","journal-title":"J Immunother Cancer."},{"key":"9887_CR32","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1111\/jcmm.16333","volume":"25","author":"X Wang","year":"2021","unstructured":"Wang X, Chen S, Xiang H, Liang Z, Lu H. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med. 2021;25:2740\u20132749. https:\/\/doi.org\/10.1111\/jcmm.16333.","journal-title":"J Cell Mol Med."},{"key":"9887_CR33","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/ATVBAHA.113.301347","volume":"33","author":"F Pot\u00ec","year":"2013","unstructured":"Pot\u00ec F, Gualtieri F, Sacchi S et al. KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R \u2212\/\u2212 Mice. Arterioscler Thromb Vasc Biol. 2013;33:1505\u20131512. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301347.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"9887_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/jpet.118.254268","volume":"369","author":"H Al-Shamma","year":"2019","unstructured":"Al-Shamma H, Lehmann-Bruinsma K, Carroll C et al. The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis. J Pharmacol Exp Ther. 2019;369:311\u2013317. https:\/\/doi.org\/10.1124\/jpet.118.254268.","journal-title":"J Pharmacol Exp Ther."},{"key":"9887_CR35","doi-asserted-by":"publisher","unstructured":"Karuppuchamy T, Behrens E h, Gonz\u00e1lez-Cabrera P, et al. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017;10(1):162\u2013171. https:\/\/doi.org\/10.1038\/mi.2016.35","DOI":"10.1038\/mi.2016.35"},{"key":"9887_CR36","doi-asserted-by":"publisher","unstructured":"Bigaud M, Guerini D, Billich A, Bassilana F, Brinkmann V. Second generation S1P pathway modulators: Research strategies and clinical developments. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2014;1841(5):745\u2013758. https:\/\/doi.org\/10.1016\/j.bbalip.2013.11.001","DOI":"10.1016\/j.bbalip.2013.11.001"},{"key":"9887_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53:585\u2013590. https:\/\/doi.org\/10.1007\/s00535-018-1449-z.","journal-title":"J Gastroenterol."},{"key":"9887_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1014154108","volume":"108","author":"JW Choi","year":"2011","unstructured":"Choi JW, Gardell SE, Herr DR et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1) modulation. Proceedings of the National Academy of Sciences. 2011;108:751\u2013756. https:\/\/doi.org\/10.1073\/pnas.1014154108.","journal-title":"Proceedings of the National Academy of Sciences."},{"key":"9887_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/biomedicines8070227","volume":"8","author":"S Cohan","year":"2020","unstructured":"Cohan S, Lucassen E, Smoot K, Brink J, Chen C. Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article. Biomedicines. 2020;8:227. https:\/\/doi.org\/10.3390\/biomedicines8070227.","journal-title":"Biomedicines."},{"key":"9887_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","volume":"261","author":"R Gold","year":"2014","unstructured":"Gold R, Comi G, Palace J et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014;261:267\u2013276. https:\/\/doi.org\/10.1007\/s00415-013-7115-8.","journal-title":"J Neurol."},{"key":"9887_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1756285616682936","volume":"10","author":"MJ Hilz","year":"2017","unstructured":"Hilz MJ, Wang R, de Rojas Leal C et al. Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects. Ther Adv Neurol Disord. 2017;10:191\u2013209. https:\/\/doi.org\/10.1177\/1756285616682936.","journal-title":"Ther Adv Neurol Disord."},{"key":"9887_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/08998280.2010.11928655","volume":"23","author":"CS Mclachlan","year":"2010","unstructured":"Mclachlan CS, Ocsan R, Spence I et al. Increased Total Heart Rate Variability and Enhanced Cardiac Vagal Autonomic Activity in Healthy Humans with Sinus Bradycardia. Baylor University Medical Center Proceedings. 2010;23:368\u2013370. https:\/\/doi.org\/10.1080\/08998280.2010.11928655.","journal-title":"Baylor University Medical Center Proceedings."},{"key":"9887_CR43","doi-asserted-by":"publisher","unstructured":"Constantinescu V, Haase R, Akg\u00fcn K, Ziemssen T. S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review. Ther Adv Neurol Disord. 2022;15. https:\/\/doi.org\/10.1177\/17562864221133163","DOI":"10.1177\/17562864221133163"},{"key":"9887_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/ueg2.70026","volume":"13","author":"MC Fantini","year":"2025","unstructured":"Fantini MC, Centonze D, Giacobazzi G, Benemei S, Romeo E. Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety. United European Gastroenterol J. 2025;13:1077\u20131091. https:\/\/doi.org\/10.1002\/ueg2.70026.","journal-title":"United European Gastroenterol J."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09887-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:13:30Z","timestamp":1787800410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09887-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9887"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09887-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}